Lurbinectedin is a chemotherapy drug used to treat patients with small cell lung cancer and is currently undergoing clinical trials for other types of cancer. According to Drug Patent Watch [1], there are currently no FDA-approved combinations of lurbinectedin with other treatments. However, there are ongoing clinical trials that aim to investigate the effectiveness of lurbinectedin in combination with other drugs.

One study published in the Journal of Clinical Medicine [2] investigated the combination of lurbinectedin with irinotecan in patients with relapsed small cell lung cancer. The study found that the combination of these two drugs was well-tolerated and showed promising anti-tumor activity. Another ongoing clinical trial registered on ClinicalTrials.gov [3] is investigating the combination of lurbinectedin with pembrolizumab in patients with advanced solid tumors. The trial aims to evaluate the safety and efficacy of this combination therapy.

In conclusion, while there are currently no FDA-approved combinations of lurbinectedin with other treatments, ongoing clinical trials are investigating the potential benefits of combining lurbinectedin with other drugs. The results of these trials will provide valuable information on the effectiveness and safety of combination therapy with lurbinectedin.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469650/
[3] https://www.clinicaltrials.gov/ct2/show/NCT04358237